Douglas Bonhaus, Ph.D.
Chief Executive Officer
Dr. Douglas Bonhaus has served as the Chief Scientific Officer of Neuropore Therapies, Inc. since 2011. Dr. Bonhaus is an established leader in the pharmaceutical industry with more than 25 years of experience building and leading drug discovery organizations dedicated to the discovery and development of new therapeutics for neurological and psychiatric disorders. Before joining Neuropore Therapies, Dr. Bonhaus has held industry positions at Syntex, Roche and ACADIA pharmaceuticals where he served as the Vice President of Biosciences. Dr. Bonhaus was also co-founder and Chief Scientific Officer for Denysias Bioscience, a start-up company focused on developing a novel therapeutic for a psychiatric indication in Parkinson's disease. Key scientific and leadership contributions in these positions have resulted in a number of novel therapeutic agents being advanced to clinical development or the market. He is an inventor on several patents, a principal author on over a hundred peer-reviewed publications and has been awarded a number of NIH and private foundation research grants.
Dr. Bonhaus received his Ph.D. in pharmacology and toxicology from the University of Arizona and completed postdoctoral training in the Department of Medicine at Duke University.
Paul Gotfredson, CPA
Chief Financial Officer
Mr. Gotfredson has served as the Chief Financial Officer of Neuropore Therapies since 2009. Mr. Gotfredson is a financial and accounting professional with significance management experience working with private and public companies. He also advises other early-stage companies on equity and debt financing, financial reporting, operations and corporate governance. Before joining Neuropore Therapies, Mr. Gotfredson held the positions of Director of Finance with Genicon Sciences, a high-growth venture-backed biotech acquired by Life Technologies, Corporate Controller at Molecular Biosystems, a publicly traded biotech acquired by Alliance Pharmaceuticals, and Assistant Controller with Casio Manufacturing Corporation.
Mr. Gotfredson began his career working as an auditor in the San Diego offices of Ernst and Young. He received his BS in Accounting from the University of San Diego in 1989 and was licensed as a CPA in the state of California in 1992.
Wolf Wrasidlo, Ph.D.
Executive Director, Medicinal Chemistry
Dr. Wolfgang Wrasidlo is one of the founding members of Neuropore Therapies Inc. and a research chemist with a distinguished 40 plus year career in academia and the pharmaceutical industry. He has held several senior level positions in academia including Director of the Chemical Biology Program at the UCSD Moores Cancer Center, UCSD School of Medicine, The Scripps Research Institute, Humboldt University Berlin Medical School, University of Tuebingen Children’s Hospital, and Columbia University. He has held positions in industry as a Distinguished Research Fellow at TargeGen, Inc., a Founder and the Head of Research at Brunswick Biotechnetics, a Research Scientist at General Atomics, and a member of the Member- Macromolecular Chemistry Group at the Boeing Scientific Research Institute.
Dr. Wrasidlo received a B.S. in Chemistry from San Diego State University and a Ph.D. in Organic Chemistry from the University of Erlangen and San Diego State University. He has authored over 200 scientific publications and the inventor on over 80 patents or patent applications.
Diana L. Price, Ph.D.
Executive Director, Biosciences
Dr. Price is the Executive Director of Biosciences at Neuropore Therapies where she has lead research efforts supporting in vivo pharmacology, preclinical development, and translational biomarker studies since 2011.
Dr. Price received her doctorate in Neurosciences from the UCSD School of Medicine in 2000. She conducted a postdoctoral appointment from 2000-2003, and then transitioned to an academic research faculty member at the National Center for Microscopy and Imaging Research at UCSD while conducting collaborative multi-scale imaging, behavioral pharmacology and bioinformatics research in pursuit of characterizing translational models of CNS disorders.
Dr. Price moved to industry in 2007, with a position at ACADIA Pharmaceuticals as a drug-discovery team member for neurological and psychiatric disorders utilizing behavioral pharmacology and neuroanatomical techniques to evaluate drug candidates and provide proof of concept data for preclinical development of Pimavanserin (Nuplazid™) for Parkinson’s and Alzheimer’s disease psychosis.